Nuvation Bio Inc. (NUVB)
PHARMACEUTICAL PREPARATIONS
Nuvation Bio Inc. (NUVB) is listed on the New York Stock Exchange, where it has traded since February 10, 2021.
- Listed On
- the New York Stock Exchange
- Listed Since
- February 10, 2021
- Employees
- 305
- Market Cap
- $1.6B
About Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 230 institutions reported holding NUVB, with 231.7 million shares worth $1.3 billion in aggregate. The largest reported holder was FMR, with 52.2 million shares worth $296.7 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 52,230,295 | $297M | Added 0.46% |
| BlackRock | 27,630,837 | $157M | Added 10.08% |
| Decheng Capital | 25,954,439 | $147M | Unchanged |
| Vanguard | 16,799,559 | $95M | Added 5.96% |
| Omega Fund Management | 8,081,089 | $46M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is NUVB?
Nuvation Bio Inc. (NUVB) is listed on the New York Stock Exchange, where it has traded since February 10, 2021.
Who are the largest institutional holders of NUVB?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of NUVB were FMR, BlackRock and Decheng Capital.
How many institutions own NUVB?
230 institutions reported a position in NUVB for the quarter ended June 30, 2026, worth $1.3 billion in total.
Did institutions buy or sell NUVB last quarter?
Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for NUVB.
Every reported institutional holder, plus insider and congressional trades in NUVB, on SentiSense.